ACTRN12621001535864
Recruiting
Phase 3
A pilot randomized placebo-controlled double-blind trial of single dose oral Ivermectin for post-exposure prophylaxis of SARS-CoV-2
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- COVID-19
- Sponsor
- Monash University
- Enrollment
- 1000
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. In the preceding 72 hours, had close contact with a person infectious with SARS\-CoV\-2\.
- •AND that contact was in the context of i) a participant’s home or ii) an indoor work environment or iii) a family gathering or a social or a religious function or a ceremony each being of less than 30 people.
- •AND since that contact, tested negative for SARS\-CoV\-2 on polymerase chain reaction(PCR) of pharyngeal swab or on a rapid antigen test (RAT).
- •AND are asymptomatic of fever, new cough, sore throat, rhinorrhoea, loss of smell, loss of taste, or more difficulty breathing than usual.
Exclusion Criteria
- •Not agreeable to being at home for delivery of the investigational product
- •The close contact with an infectious index case of SARS\-CoV\-2 occurred in a hospital
- •Residing outside the current geographic recruitment area
- •The index case who has SARS\-CoV\-2 lives in the same residence as the potential participant.
- •Another person who lives in the same residence as the potential participant has returned a positive pharyngeal PCR or a RAT for SARS\-CoV\-2 in the last 2 weeks.
- •Unable to provide the name, address and phone number of the potential participant’s general practitioner/primary care physician OR does not have such a general practitioner/primary care physician.
- •. Has not attended a doctor at the practice of the above general practitioner/primary care physician for more than 12 months. (NB Given the pandemic, that attendance may have been by telehealth).
- •Lives alone (as potentially at higher risk should there be a serious adverse event).
- •Unable to provide the name and phone number of a back\-up contact person.
- •History of past infection with SARS\-CoV\-2\.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 3
The Myer Foundation Study into Multiple SclerosisRelapsing remitting multiple sclerosisNeurological - Multiple sclerosisACTRN12606000359538Melbourne Health20
Completed
Not Applicable
A pilot double-blind randomised controlled trial comparing two physiotherapy interventions to treat femoroacetabular impingement.Femoroacetabular impingementPhysical Medicine / Rehabilitation - PhysiotherapyMusculoskeletal - Other muscular and skeletal disordersACTRN12615001218583a Trobe University, La Trobe Sport and Exercise Medicine Research Centre40
Completed
Not Applicable
A pilot randomized, double-blind, placebo-controlled, parallel-group clinical study to study the safety and tolerability of IP in healthy adultsCTRI/2023/03/050853Vedic Lifesciences Pvt Ltd64
Active, not recruiting
Phase 1
A pilot study of the use of metformin to reduce airway glucose in COPDChronic obstructive pulmonary diseaseMedDRA version: 21.1 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2018-001755-12-GBImperial College40
Active, not recruiting
Phase 1
Trial of oxytocin for the treatment of emotional withdrawal symptoms and for relapse prevention in abstinent heroin dependent individualsOpioid dependence. The study will be investigating the efficacy of Syntocinon (oxytocin) on treating the withdrawal symptoms and cravings that opioid (e.g. almost always heroin) dependent individuals experience following detoxification.MedDRA version: 20.0 Level: LLT Classification code 10057379 Term: Addiction relapse System Organ Class: 100000004873MedDRA version: 20.0 Level: LLT Classification code 10001126 Term: Addiction any drug System Organ Class: 100000004873Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]EUCTR2014-002708-26-GBniversity of Surrey3